investors.foundationmedicine.comFoundation Medicine | A World-leading Molecular Insights Company

Log In Create an account Products & Services Toggle submenu Explore About Our Products & Services Our Tests Toggle submenu Comprehensive Genomic Profiling FoundationOne CDx FoundationOne Liquid CDx FoundationOne Heme Compare Our Tests Monitoring FoundationOne Tracker Supplementary Testing IHC Testing Provider Services Toggle submenu Provider Services Overview Online Ordering, & System Integrations Clinical Research & Trial Matching Decision Support & Provider Education Biopharma Services Toggle submenu Biopharma Partner Services Overview Discovery & Translational Research Clinical Development & CDx Access & Commercialization Actionable Results Image Now Available FoundationOne Tracker Add clarity to treatment response with personalized tissue-informed ctDNA monitoring, providing objective insights to help you understand your patients’ response to treatment. Resource Center Toggle submenu Explore View All Resources For Providers Toggle submenu Provider FAQ What is Comprehensive Genomic Profiling? Which genes are tested Why is circulating tumor DNA (ctDNA) important? View all Provider FAQs Provider Resources Why Comprehensive Genomic Profiling? Immunotherapy Biomarkers Billing and Reimbursement Support View all Provider Resources Knowledge Center For Biopharma Partners Toggle submenu Biopharma Partner FAQ How can ctDNA support your drug development? How can genomic data generated by Foundation Medicine tests be used for biomarker discovery? How do I contact someone in the biopharma group to discuss a project? View all Biopharma Partner FAQs Biopharma Resources Biopharma Partner Services Biopharma Brochure View all Biopharma Resources For Patients Toggle submenu Patient FAQs What can I learn from a Foundation Medicine test? What mutations and biomarkers are included in Foundation Medicine tests? Does insurance cover my Foundation Medicine comprehensive genomic profiling test? View all Patient FAQs Patient Resources Patient Brochure Doctor Discussion Guide Financial Assistance Application View all Patient Resources Knowledge Center News & Events Toggle submenu Explore News & Events Press Releases Foundation Forward Blog Events Research Useful InformationLeadership Team Browse PublicationsToggle submenu Explore Our Story Our History Leadership Team Diversity, Equity & Inclusion Environmental, Social & Governance Contact Us Useful Information Testing Portfolio Supplier Information Why Comprehensive Genomic Profiling? Browse Publications Foundation Medicine Fact sheet Careers For Patients Order a Test We noticed you are browsing from outside the United States of America (USA) The information presented on this website is intended for healthcare professionals, patients, and caregivers located in the USA. To view information intended for users located outside of the USA, please visit our international website, www.rochefoundationmedicine.com . For biopharma partner information, please continue to the US Site. Continue browsing the US Site Visit International Site Image Find Answers. Take Action.® Your Essential Partner in Cancer Care Colleen enjoys photography and has been living with cancer since 2014. Foundation Medicine is transforming cancer care by providing patients, physicians and researchers with a deep understanding of the genomic mutations that drive cancer. Image For Providers Foundation Medicine’s proven portfolio of tests and services offers the quality and commitment you need to help guide treatment strategies for your advanced cancer patients. Provider Resources FoundationOne®CDx FoundationOne®Liquid CDx Companion Diagnostics Explained: Their Critical Role in Cancer Care and Our La… Provider FAQs Image For Biopharma & Research Partners We can support you from initial discovery to launch of a new therapy with our global portfolio of tests and services and our scientific and regulatory experts to fit your specific needs. As a leader in companion diagnostic (CDx) approvals, we are your ideal partner to help make your next breakthrough a standard of care. Biopharma & Research Partner Resources Discovery & Translational Research Clinical Development & CDx Access & Commercialization Image For Patients Every cancer is unique. That’s why we are committed to providing specific genomic insights into your cancer to help your doctor guide a personalized care plan. Patient Resources Information For Patients Patient Booklet Patient FAQs Proven Leadership Our unique knowledge base, FoundationCore® , is one of the world’s largest cancer genomic databases. It is designed to evaluate the genomic landscape across cancer types to better understand tumor biology, molecular biomarkers, and which treatments might work for which patients. This all helps researchers and biopharma companies develop new therapies, design better clinical trials, and advance precision medicine. Over 1 Million FOUNDATION MEDICINE REPORTS DELIVERED 60% OF ALL US CDX APPROVALS FOR NGS TESTING* 500+ PEER-REVIEWED PUBLICATIONS Valuable Insights, Actionable Options Our tests help to identify the genomic alterations driving a patient’s cancer and match them with relevant targeted therapies, immunotherapies, and clinical trial options. We also provide decision support services and technology solutions to help support patient care. Learn more about our products and services Patient Story Treating cancer means more than just dealing with the disease; it also means treating the whole person. Christine Bray, ovarian cancer survivor, shares her journey to remission after obtaining a Foundation Medicine comprehensive genomic profiling test. We Continue To Drive For Future Breakthroughs In Patient Care Image Actionable Insights Upfront We understand that treatment planning for your cancer patients can be complex. That’s why we’re updating our FoundationOne CDx and FoundationOne Liquid CDx reports to pull the Professional Services” summary section to the first page. This update will bring information for all reported biomarker and genomic findings and our new Report Highlights” section upfront, to help you focus on the critical findings for your patients. Learn More About Our Reports * Data on file, Foundation Medicine Inc., data as of Nov. 18, 2022. Important Safety Information Select FoundationOne®CDx FoundationOne®Tracker FoundationOne®Liquid CDx FoundationOne®CDx FoundationOne®Tracker FoundationOne®Liquid CDx FoundationOne CDx FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com FoundationOne Tracker FoundationOne®Tracker is a clinical test performed exclusively as a laboratory service. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). FoundationOne Tracker is a personalized assay for oncology that is based on patient-specific somatic variants (substitutions and short insertions/deletions) identified from baseline tumor tissue testing and used to detect and longitudinally measure plasma circulating tumor DNA (ctDNA) abundance as a biomarker for tumor burden. Treatment decisions are the responsibility of the treating physician. ctDNA detection sensitivity may be limited if blood collection occurs within two weeks...